NEW YORK (GenomeWeb) – Veracyte announced after the close of the market on Wednesday that its revenues for the second quarter increased 71 percent year over year, but still fell short of the consensus analysts' estimate.

It also said that it and Genzyme have agreed to amend their co-promotion agreement reached in early 2012.

The South San Francisco, Calif.-based firm said that for the three months ended June 30, revenues reached $8.7 million, compared to $5.1 million in the year-ago period. On average, Wall Street had expected revenues of $9.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.